Opens rare disease drug committee to public input

File HF4852 ("Opens rare disease drug committee to public input") is before the Minnesota Legislature and has not been decided. Latest step (April 7, 2026): Introduction and first reading, referred to.

Minnesota file HF4852, before the Minnesota Legislature. Still to be decided as of 2026-04-07.

What it does

Rare disease patients can comment on drug coverage decisions The state's Formulary Committee must now accept public comments on recommendations, giving patients and families a formal opportunity to influence which rare disease treatments the state covers.

The bigger picture

Committee gains expertise from rare disease advisory council The Formulary Committee is now required to consult the Minnesota Rare Disease Advisory Council, bringing patient and specialist perspectives into coverage deliberations that previously may have lacked that expertise.

What to watch

Conflict-of-interest rule change may reduce transparency The bill permits committee members with financial ties to drug companies to participate in discussions and decisions, which critics may view as reducing objectivity despite the new public comment process.

Official summary

Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.

Read the official record for HF4852

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk